» Articles » PMID: 33803085

Extracellular Vesicles As Biomarkers Carriers in Bladder Cancer: Diagnosis, Surveillance, and Treatment

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Apr 3
PMID 33803085
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Exosomes are extracellular vesicles, enriched in biomolecular cargo consisting of nucleic acids, proteins, and lipids, which take part in intercellular communication and play a crucial role in both physiologic functions and oncogenesis. Bladder cancer is the most common urinary malignancy and its incidence is steadily rising in developed countries. Despite the high five-year survival in patients diagnosed at early disease stage, survival substantially drops in patients with muscle-invasive or metastatic disease. Therefore, early detection of primary disease as well as recurrence is of paramount importance. The role that exosomal biomarkers could play in bladder cancer patient diagnosis and surveillance, as well as their potential therapeutic applications, has not been extensively studied in this malignancy. In the present review, we summarize all relevant data obtained so far from cell lines, animal models, and patient biofluids and tissues. Current literature suggests that urine is a rich source of extracellular vesicle-derived biomarkers, compared with blood and bladder tissue samples, with potential applications in bladder cancer management. Further studies improving sample collection procedures and optimizing purification and analytical methods should augment bladder cancer diagnostic, prognostic, and therapeutic input of extracellular vesicles biomarkers in the future.

Citing Articles

Advances and challenges in the use of liquid biopsy in gynaecological oncology.

Zhang Y, Tian L Heliyon. 2024; 10(20):e39148.

PMID: 39492906 PMC: 11530831. DOI: 10.1016/j.heliyon.2024.e39148.


Optimized workflow of EV enrichment from human plasma samples for downstream mass spectrometry analysis.

Erwied P, Gu Y, Simon L, Schneider M, Helm D, Michel M Discov Oncol. 2024; 15(1):374.

PMID: 39190201 PMC: 11349724. DOI: 10.1007/s12672-024-01248-x.


Exosomes: Toward a potential application in bladder cancer diagnosis and treatment.

Wei X, Zhang D, Zhu Y Smart Med. 2024; 3(1):e20230027.

PMID: 39188515 PMC: 11235804. DOI: 10.1002/SMMD.20230027.


Advances in Liquid Biopsy for Diagnosis of Bladder Cancer.

Seok J, Kwak Y, Kim S, Kim E, Kim A Int Neurourol J. 2024; 28(2):83-95.

PMID: 38956768 PMC: 11222820. DOI: 10.5213/inj.2448198.099.


Bladder Cancer in Exosomal Perspective: Unraveling New Regulatory Mechanisms.

Yin C, Liufu C, Zhu T, Ye S, Jiang J, Wang M Int J Nanomedicine. 2024; 19:3677-3695.

PMID: 38681092 PMC: 11048230. DOI: 10.2147/IJN.S458397.


References
1.
Maas S, Breakefield X, Weaver A . Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends Cell Biol. 2016; 27(3):172-188. PMC: 5318253. DOI: 10.1016/j.tcb.2016.11.003. View

2.
Gil-Araujo B, Toledo Lobo M, Gutierrez-Salmeron M, Gutierrez-Pitalua J, Ropero S, Angulo J . Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism. Mol Oncol. 2013; 8(1):27-38. PMC: 5528511. DOI: 10.1016/j.molonc.2013.08.012. View

3.
Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T . Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011; 71(20):6320-6. DOI: 10.1158/0008-5472.CAN-11-1021. View

4.
Wang J, Yang K, Yuan W, Gao Z . Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Bladder Cancer Diagnosis and Prognosis. Med Sci Monit. 2018; 24:9307-9316. PMC: 6320644. DOI: 10.12659/MSM.912018. View

5.
Li Q, Huyan T, Cai S, Huang Q, Zhang M, Peng H . The role of exosomal miR-375-3p: A potential suppressor in bladder cancer via the Wnt/β-catenin pathway. FASEB J. 2020; 34(9):12177-12196. DOI: 10.1096/fj.202000347R. View